Sinoway Industrial Co., Ltd.

Linagliptin 668270-12-0 Linagliptin 668270-12-0

Linagliptin 668270-12-0
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic information of Linagliptin:

Name

Linagliptin

Alias

8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione

CAS NO.

668270-12-0

Molecular Formula

C25H28N8O2

Molecular Weight

472.54

Grade Standard

Medicine grade  / 99% min / GMP application / PMDA / DMF

Package Size

25kg/drum

Storage:

Keep in a well-closed container, protected from light and stored at a temperature of 2 to 8


Use of Linagliptin:

Linagliptin is used to control of blood glucose levels in people with type 2 diabetes by combining diet and exercise. Linagliptin controls glycemic in patients by inhibiting dipeptidyl peptidase-4 (DPP-4).

Compared with other DPP-4 inhibitors, the main advantages of linagliptin are: excellent renal safety and effective reduction of glycated hemoglobin. Lilacitin is mainly excreted in the form of a prototype, and after oral administration, the amount of renal excretion is only 5% of the dose, and even if administered intravenously, only 30.8% is excreted by the kidney, so the patient receiving the treatment does not need Regular examination of liver and kidney function and dose adjustment, all patients can be fixed doses, easy to prescribe.

COA of Linagliptin:

Items

 

Specification

 

Result

 

Assay

 

≥98.5%

 

99.77%

 

Appearance

 

White to light yellow powder

 

Light yellow powder

Loss on drying

≤0.5%

0.38%

Residue on drying

≤0.1%

0.07%

Single impurity

≤0.5%

0.08%

Total impurity

≤1.5%

0.23%



  • Lacosamide 175481-36-4
    Basic information of Lacosamide :NameLacosamideAlias(2R)-2-acetamido-N-benzyl-3-methoxy-propanamide;(2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide;ADD 243037;Erlosamide;Harkoseride;SPM 927... Lacosamide 175481-36-4
  • Oxaliplatin 61825-94-3
    Basic information of Oxaliplatin :Name OxaliplatinAliastrans-l-diaminocyclohexane oxalatoplatinum; oxalato(1r,2r-cyclohexanediammine)platinum(ii); oxalatoplatin; oxalatoplatinumCAS NO.61825-94-3Molecu... Oxaliplatin 61825-94-3
  • Alogliptin Benzoate 850649-62-6
    Basic information of Alogliptin benzoate:NameAlogliptin benzoateCAS NO.850649-62-6Molecular FormulaC18H21N5O2.C7H6O2Molecular Weight461.519Grade StandardMedicine grade / 99% min / PMDA / DMFPackage S... Alogliptin Benzoate 850649-62-6
  • Mildronate 76144-81-5
    Basic information of MildronateNameMildronateAliasTHP,MET-88,mildronateCAS NO.76144-81-5Molecular FormulaC6H14N2O2Quality Standard EPGrade StandardMedicine grade / 99% minPackage Size25kg/drumUse of Mild... Mildronate 76144-81-5

MORE_DETAIL Linagliptin 668270-12-0

Basic information of Linagliptin:

Name

Linagliptin

Alias

8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione

CAS NO.

668270-12-0

Molecular Formula

C25H28N8O2

Molecular Weight

472.54

Grade Standard

Medicine grade  / 99% min / GMP application / PMDA / DMF

Package Size

25kg/drum

Storage:

Keep in a well-closed container, protected from light and stored at a temperature of 2 to 8


Use of Linagliptin:

Linagliptin is used to control of blood glucose levels in people with type 2 diabetes by combining diet and exercise. Linagliptin controls glycemic in patients by inhibiting dipeptidyl peptidase-4 (DPP-4).

Compared with other DPP-4 inhibitors, the main advantages of linagliptin are: excellent renal safety and effective reduction of glycated hemoglobin. Lilacitin is mainly excreted in the form of a prototype, and after oral administration, the amount of renal excretion is only 5% of the dose, and even if administered intravenously, only 30.8% is excreted by the kidney, so the patient receiving the treatment does not need Regular examination of liver and kidney function and dose adjustment, all patients can be fixed doses, easy to prescribe.

COA of Linagliptin:

Items

 

Specification

 

Result

 

Assay

 

≥98.5%

 

99.77%

 

Appearance

 

White to light yellow powder

 

Light yellow powder

Loss on drying

≤0.5%

0.38%

Residue on drying

≤0.1%

0.07%

Single impurity

≤0.5%

0.08%

Total impurity

≤1.5%

0.23%


Leave a Message Email Us

We will contact you within 24 hours.

  • TEL:+86-0592-5853819
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//